Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 8/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774031 | 1.00 | GPR183 (0.58) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL3767721 | 0.89 | MEN1 (0.56) | GPR183NPC1RAB9ACCR2HRH3 | |
| SCHEMBL3767727 | 0.89 | MEN1 (0.56) | GPR183NPC1RAB9ACCR2HRH3 | |
| SCHEMBL3773067 | 0.87 | MEN1 (0.54) | GPR183NPC1HRH3 | |
| SCHEMBL3773064 | 0.87 | MEN1 (0.54) | GPR183NPC1HRH3 | |
| SCHEMBL3765623 | 0.84 | ALDH1A1 (0.58) | GPR183HRH3 | |
| SCHEMBL3765617 | 0.84 | ALDH1A1 (0.58) | GPR183HRH3 | |
| SCHEMBL3773866 | 0.84 | MEN1 (0.56) | GPR183NPC1RAB9A | |
| SCHEMBL3773864 | 0.84 | MEN1 (0.56) | GPR183NPC1RAB9A | |
| SCHEMBL3769147 | 0.83 | TDP1 (0.52) | NPC1RAB9ATDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | GPR183 59/4885NPC1 3462/4885RAB9A 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.